Local activation of the components of the renin angiotensin system in the heart is regarded as an important modulator of cardiac phenotype and function; however, little is known about their presence, regulation, and potential activation in the human heart. To investigate the gene expression of major angiotensin-II-forming enzymes in left ventricles of normal (n = 9) and failing human hearts (n = 20), we established a competitive RNA-polymerase chain reaction (PCR) for mRNA quantification of angiotensin-I converting enzyme (ACE) and human heart chymase. For each gene, competitor RNA targets with small internal deletions were used as internal standards to quantify the original number of transcripts and to control reverse transcription and PCR. In PCR, each target and the corresponding competitor were amplified by competing for the same primer oligonucleotides. The variability of ACE RNA-PCR was 11% indicating a high reproducibility of this method. In addition, ACE mRNA levels obtained by competitive RNA-PCR correlated favorably with traditional slot blot hybridization (r = 0.69, n = 10; P < 0.05). Compared with nonfailing hearts, the number of ACE transcripts referred to 100 ng of total RNA was increased threefold in patients with chronic heart failure (4.2±2.5 vs. 12.8±6 x 105; P < 0.0005). In contrast, no significant difference was found in chymase gene expression between normal and failing hearts. Thus, the expression of the cardiac ACE but not of human heart chymase is upregulated in failing human heart indicating an activation of the cardiac renin-angiotensin system in patients with advanced heart failure. (J. Clin. Invest. 1994. 94:301-310.) 
Introduction
Evidence has been presented for an endogenous tissue renin angiotensin system in the heart by demonstrating the cardiac gene expression of all components of this system (for review see references [1] [2] [3] , including angiotensinogen (4-6), angiotensin-II receptors (7, 8) , renin (9) (10) (11) , angiotensin-I converting enzyme (ACE) ( 12, 13 ) and other angiotensin-II forming enzymes such as the human heart chymase (14) (15) (16) . Recent studies have shown that the cardiac expression of angiotensinogen and ACE is increased in experimental heart failure ( 12, 13, 17, 18) . Cardiac ACE activity as well as the rate of angiotensin-II production is enhanced in hypertrophied rat hearts (12) and associated with altered diastolic properties possibly contributing to the vulnerability of diastolic function in hypertrophy during hypoperfusion ( 19) . Other potential actions of the cardiac renin angiotensin system include a trophic effect, as suggested by identifying angiotensin-il as a growth-promoting factor in cardiac muscle cells (20) (21) (22) . This hypothesis is supported by recent data demonstrating that ACE inhibitors given in very low doses not affecting blood pressure prevented the development of cardiac hypertrophy in pressure-overloaded rats (23, 24) . These experimental observations raise the possibility that the beneficial effects of ACE inhibitors in patients with heart failure may not only be due to neuroendocrine and hemodynamic modulation, but also to the interference with an activated tissue cardiac renin angiotensin system. In this regard, Foult et al. (25) have shown that the intracoronary infusion of an ACE inhibitor in patients with dilated cardiomyopathy resulted in a fall of coronary vascular resistance and a reduction in left ventricular diastolic pressure, consistent with the hypothesis that an activated cardiac tissue renin-angiotensin system may modulate coronary perfusion and diastolic function in humans.
An alternative pathway for the conversion of angiotensin-I to angiotensin-JI in the human heart is achieved by the human heart chymase (26) which has been purified and cloned recently (14, 15) . This chymotrypsin-like serine proteinase is the most efficient and specific angiotensin-il-forming enzyme described and not inhibited by ACE inhibitors (14, 16) . Recently, Urata et al. (27) have delineated localization and expression of human heart chymase in the human myocardium, suggesting that mRNA level is unchanged in human heart failure. In contrast, little is known about the regulation and potential activation of the components of the renin-angiotensin system in the human heart. Recently, the expression of the angiotensinogen gene and its localization in the human heart has been reported, yet without reference to its abundance in diseased myocardium (28).
In this study we investigated the gene expression of ACE and human heart chymase in failing and nonfailing human hearts by using the quantitative method of competitive RNA-PCR (29) (30) (31) . By adding a known quantity of competitor RNA as an internal standard to the reaction, this method allowed the detection and quantification of low abundant transcripts (31) . Using this method, we demonstrate that the gene expression of cardiac ACE is upregulated in failing human hearts while in the same tissues the gene expression of chymase remains unchanged.
Methods

Patients
Failing human hearts were obtained from patients undergoing heart transplantation including 13 patients with dilated cardiomyopathy and 7 patients with coronary artery disease (see Table I ). All patients were in New York Heart Association (NYHA) functional class IV heart failure and demonstrated abnormal pretransplant hemodynamics (see Table I ). Nonfailing control hearts (see Table II Isolation ofpoly(A)+ RNA Poly(A)' RNA was purified from total RNA by an oligo (dT)-cellulose column. The column material was prepared according to the supplier's recommendation (Boehringer, Mannheim, FRG). Samples of total RNA were first heat-denatured (650C), then adjusted to an appropriate salt concentration (0.5 M NaCl, 10 mM Tris-HCl, pH 7.4, 1 mM EDTA), and incubated with the column material for two hours at room temperature by rotation. Then, the whole mixture was filled into a Poly-Prep chromatography column (Bio-Rad Ltd., Munich, FRG). Unbound RNA was removed by several washes with high-salt buffer (0.5 M NaCl, 10 mM Tris-HCl, pH 7.4, 1 mM EDTA) followed by several washes with low-salt buffer (0.1 M NaCl, 10 mM Tris-HCl, pH 7.4, 1 mM EDTA). The poly(A)+ RNA was recovered by using elution buffer (10 mM Tris-HCl, pH 7.4, 1 mM EDTA) prewarmed to 65°C.
Slot blot analysis
Poly(A) + RNA samples were prepared according to standard protocols (33) and spotted to a nylon membrane (Amersham Buchler Ltd., Braunschweig, FRG) using a slot blot apparatus (Serva Ltd., Heidelberg, FRG). The RNA was fixed to the membrane by UV irradiation. Hybridization was first done with the human ACE cDNA and then with a (dT)25-oligonucleotide to control for the quantity of mRNA.
To obtain a radioactive-labeled ACE cDNA probe, the human ACE cDNA clone pB35-19 (34) Northern blot analysis 10 jig of total RNA was prepared and subjected to electrophoresis according to Rosen et al. (37) , transferred to a nylon membrane (Amersham Buchler Ltd.) by overnight capillar blotting and fixed to the membrane by UV irradiation. The blot membrane was successively hybridized with a 0.58-kb rat atrial natriuretic factor (ANF) PstI cDNA fragment (38) which is 85% identical to the human ANF cDNA sequence (39) and with a oligonucleotide (5'-GGTATCTGATCGTCTTCGAA-3') deduced from the rat ribosomal 18 S RNA (18 S rRNA) sequence (40) . Labeling of the cDNA and the oligonucleotide, prehybridization, hybridization, washing, and exposure of Northern blots were performed as described for slot blot analysis with the following exceptions: Prehybridization and hybridization with 18 S rRNA oligonucleotide was performed at 53°C. After hybridization, membranes were washed three times for 30 min in 6x SSC at room temperature and for 1 min in 6x SSC at 530C.
Relative amounts of ANF mRNA were evaluated by densitometric scanning (Personal densitometer; Molecular Dynamics Ltd.) of the band densities and expressed in relation to those of 18 S rRNA.
Competitive RNA-PCR for quantification of ACE and chymase mRNA Quantification of ACE and human heart chymase mRNA was performed by reverse transcription followed by polymerase chain reaction (PCR) in the presence of a defined concentration of either a shortened ACE or human heart chymase competitor RNA that served as an internal standard. Consequently, competitor RNA and target mRNA were reverse transcribed in the same reaction tube and coamplified by the same primer oligonucleotides to avoid sample to sample variations in reverse transcription and PCR. In separate control studies, for each tissue sample and for both the ACE and the chymase mRNA template, the optimal range of total RNA amount was determined in which the output of RNA-PCR was linear to the original amount of total RNA used. To ensure that quantitative analysis at 30 cycles is performed during the exponential phase of PCR amplification, in previous studies each gene target was subjected to 25 to 36 cycles of amplification. Furthermore, when target and corresponding competitor RNA of each gene was subjected to serial dilutions, this resulted in parallel amplification curves indicating similar amplification efficiencies for each gene target and the corresponding competitor cDNA.
Selection and synthesis of the PCR primers
Appropriate sense and antisense primer oligonucleotides were selected from the human cDNA sequences of ACE (sense primer: 1656-1675 5 '-GCAAGGAGGCAGGCTATGAG-3 ', antisense primer: 2412-2431 5'-CGGGTAAAACTGGAGGATGG-3') (34) and heart chymase (sense primer: 30-50 5'-TCTCCCCCTGCTGCTCTITCT-3', antisense primer: 631-651 5 '-CACCCCAGCACACAGAAGAGG-3 ') (15) by computer analysis using the Oligo program (National Biosciences Inc., Plymouth, MN) and were synthesized on a DNA synthesizer (Applied Biosystems Inc., Foster City, CA). To ensure that no genomic DNA contamination was present in the RNA solution the chosen primer oligonucleotides spanned several splice junctions (41, 15) .
Construction and in vitro transcription of the competitor templates
For construction of internal standard competitor RNAs, shortened fragments of the human cDNAs of ACE and chymase were made and transcribed into RNA. The ACE competitor template was obtained from a 951-bp (1481-2431) cDNA fragment which has been amplified with the sense primer 5'-CGCTACAACTFCGACTGGTGG-3' and the antisense primer 5 '-CGGGTAAAACTGGAGGATGG-3' by using the human ACE cDNA (34) 
Statistical analysis
All data are presented as mean±SD. Statistical differences were calculated using the unpaired Student's t test or the Mann-Whitney test as appropriate. The correlation between PCR and slot blot data were examined by linear regression analysis. Significance was accepted at the level of P < 0.05.
Results
As a stringent internal control of reverse transcription and PCR, and for quantification of the original number of transcripts, competitor RNA targets with small internal deletions were prepared from the human cDNA sequences of ACE and chymase (Fig. 1) . After reverse transcription into cDNA, each target and the corresponding competitor cDNA were amplified by competing for the same primer oligonucleotides (Fig. 1) which were selected from the human cDNA sequences of ACE and chymase. Figs. 2 and 3 show representative competitor titration experiments that use a constant amount of total RNA and a different number of either ACE or chymase competitor RNA molecules. The PCR products were separated by gel electrophoresis, stained and evaluated by laserdensitometric scanning of their band densities (Figs. 2 and 3, top) . To obtain the original Using this technique of competitive RNA-PCR, we quantified the mRNA levels of ACE and chymase in left ventricular myocardium of nonfailing heart donors and patients with chronic congestive heart failure. As shown in Fig. 4 A, the number of ACE transcripts referred to 100 ng of total RNA was increased (P < 0.0005) in failing human hearts (12.8±6 X 105; n = 20) compared to nonfailing control hearts (4.2±2.5 x 105; n = 9) with no significant differences between dilated cardiomyopathy (3.5±6.2 x 105, n = 13) and coronary artery disease (11.4±5.8 X 105, n = 7). Similarly, no significant differences in ACE gene expression were observed in patients with ACE-inhibitor therapy (13.6±6.2 x 105, n = 13) versus patients without any ACE-inhibitor therapy before transplantation (11.2±5.7 x 105, n = 7). As shown in Fig. 4 difference in chymase gene expression between patients with dilated cardiomyopathy and patients with coronary artery disease (5.3±7.8 X 104, n = 13 vs. 9±12.1 x 104, n = 7). In comparison to the ACE gene expression the mean values of chymase mRNA levels were lower in normal as well as failing human hearts (factor 13 and 19, respectively).
As shown in Table I , most patients demonstrated severely abnormal pretransplant hemodynamics. Furthermore, we investigated ANF gene expression by Northern blot analysis demonstrating a single band at 0.95 kb both in failing and nonfailing heart samples (data not shown). The ANF gene expression was upregulated in failing hearts while the ANF gene expression was very low in nonfailing donor hearts ( 1.70±1.75 vs 0.02+0.02; P < 0.001; Tables I and II) . There was no significant correlation between ANF and ACE gene expression.
To test the variability of competitive RNA-PCR, total RNA from three patients was taken to determine ACE mRNA levels in three independently performed competitor titration experiments, respectively. The variability of the three measurements averaged 11% indicating a high reproducibility of this method. In 10 patients sufficient myocardial tissue and, consequently, RNA was available to compare the results obtained by competitive RNA-PCR with ACE mRNA levels determined by slot blot analysis of poly(A)+ RNA (Fig. 5 ). There was a significant correlation between both methods (r = 0.69, P < 0.05) (Fig. 5  A) (44) (45) (46) . Conversely, the very low expression of ANF in our nonfailing tissues support the notion that the samples of these 'donors' were indeed normal. The lack of changes in chymase expression in our heart samples with increased ACE mRNA levels may suggest a "selective" upregulation of ACE in relation to the human heart chymase.
Similar to the inter-individual variation of myocardial ACE gene expression, the level of plasma ACE is highly variable between individuals (47). An insertion/deletion polymorphism within the ACE gene locus was found to account for 47% of the variance of plasma ACE levels in normal (Bottom) The band densities of the chymase target and competitor DNA were evaluated using a laserdensitometer and a computer based imaging system. The mean value of duplicate samples were plotted as logarithm of the ratio of competitor to gene target PCR products versus the logarithm of the known number of competitor molecules. At the competition equivalence point (log ratio = 0) the original number of target mRNAs corresponds to the initial number of competitor RNA molecules used. In this case, 250 ng of total RNA contained 8.81 x 104 chymase transcripts.
individuals (48) and seems to be a potent risk factor of coronary artery disease (49, 50 (53) . Similarly, the cardiac expression of angiotensinogen is confined to the left ventricle, both in the normotensive rat infarct model (18) and the pressure overload rat model (54) . Interestingly, the expression of angiotensinogen in human hearts was more prominent in subendocardial layers (28) following the pattern observed for the expression of atrial natriuretic factor (55) . Taken together, these observations would be consistent with the idea, that the activation of the intracardiac renin angiotensin system is related to an enhanced myocardial wall stress rather than to an increased coronary perfusion pressure.
The enhanced ventricular ACE expression in the failing human heart is consistent with previous observations in different rat models of cardiac hypertrophy and failure (12, 13) . The experimental cardiac hypertrophy and failure is associated with an increased tissue ACE activity (12, 13) and enhanced angiotensin-TI formation from angiotensin-I perfusate in vitro ( 12) . It has been proposed, therefore, that this enhanced angiotensin conversion may contribute to the vulnerability of diastolic function of hypertrophied hearts during hypoperfusion (12) , probably due to angiotensin-II effects on intracellular free Ca 2+ in the ischemic myocytes (19) . Conversely, intracoronary infusion of an ACE inhibitor avoiding systemic effect of the drug resulted in a decrease in coronary vascular (56) . In the rat, ACE has been detected by radioactive labeling in several regions of the heart, yet to a variable extent. For example, ACE concentrations were shown to be high in coronary arteries and low in endocardium and ventricular myocardium (57); however, the cellular distribution was not identified by this study. More recently, ACE as well as renin and angiotensinogen has been detected immunohistochemically in cultured cardiomyocytes and fibroblasts from ventricles of neonatal rats (58) . It remains to be determined whether ACE is also expressed in adult rat and human myo- is not associated with induction of left ventricular ACE mRNA levels in rat postinfarction reactive hypertrophy (unpublished observations). The latter observations are consistent with the present findings that chronic ACE inhibitor treatment is not associated with sustained induction of left ventricular ACE transcription in patients with end-stage heart failure. However, this does not exclude that a transient upregulation of cardiac ACE expression occurs early after administration of ACE inhibitors.
The human heart chymase was described as the major enzyme pathway for angiotensin-il formation in the human myocardium (26) , although our data demonstrated that the chymase is less abundantly expressed in myocardium than ACE. However, this could be explained by the higher specificity and efficiency of the human heart chymase in the conversion of angiotensin-I to angiotensin-il (14, 16) . Furthermore, turnover of chymase enzyme seems to be much slower than ACE turnover (27) . Consistent with recent observations (27) , this study revealed no significant differences in left ventricular chymase mRNA levels of failing and nonfailing human hearts. In addition, Urata et al. (27) observed no significant differences in chymase-like immunoreactivity and activity between normal and failing human hearts. Using in situ hybridization and EMimmunocytochemical techniques, these investigators (27) have shown that the human heart chymase is not exclusively expressed and stored in human cardiac mast cells as expected from other mammalian chymases but also in cardiac endothelial cells and actively dividing fibroblasts of the cardiac interstitium. In addition, high levels of chymase-like immunoreactivity are localized in the cardiac interstitium and are likely to be associated with the interstitial extracellular matrix (27) . However, it is not known which stimuli are responsible for the release of the chymase enzyme from its intracellular storages. Hence, until specific inhibitors of human heart chymase are available, the functional significance of the human heart chymase for angiotensin-Il generation in normal and failing human hearts remains uncertain.
In summary, the present study provides evidence for the intracardiac expression of ACE in the human heart and for its activation in end-stage heart failure. In contrast, there was no difference in human heart chymase gene expression between failing and nonfailing human hearts. By taking advantage of quantitative RNA-PCR to assess the cardiac expression of ACE and other components of the renin-angiotensin system, future studies should now be directed to elucidate the role of the cardiac tissue renin angiotensin system in patients in vivo.
